(Reuters) – British drugmaker GSK on Tuesday said it would acquire clinical-stage biopharmaceutical firm Aiolos Bio for a $1 billion upfront payment and up to $400 million in certainsuccess-based regulatory milestone payments. (Reporting by Eva Mathews in Bengaluru; Editing by Rashmi Aich)